Study	B:C2603343
of	O
the	O
wearable	O
cardioverter	O
defibrillator	O
in	O
advanced	O
heart	I:C0018801
-	I:C0018801
failure	I:C0018801
patients	O
(	O
SWIFT	O
)	O
.	O

Study	O
of	O
the	O
wearable	O
cardioverter	O
defibrillator	O
in	O
advanced	B:C0018801
heart	I:C0018801
-	I:C0018801
failure	I:C0018801
patients	O
(	O
SWIFT	O
)	O
.	O

The	O
wearable	O
cardioverter	O
defibrillator	O
(	O
WCD	O
)	O
may	O
allow	O
stabilization	O
until	O
reassessment	O
for	O
an	O
implantable	B:C0162589
cardioverter	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
)	O
among	O
high	O
-	I:C0018801
risk	I:C0018801
HF	I:C0018801
patients	O
.	O

The	O
wearable	O
cardioverter	O
defibrillator	O
(	O
WCD	O
)	O
may	O
allow	O
stabilization	O
until	O
reassessment	O
for	O
an	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
(	O
implantable	B:C0162589
cardioverter	I:C0162589
defibrillator	I:C0162589
)	O
among	O
high	O
-	I:C0018801
risk	I:C0018801
HF	I:C0018801
patients	O
.	O

The	O
wearable	O
cardioverter	O
defibrillator	O
(	O
WCD	O
)	O
may	O
allow	O
stabilization	O
until	O
reassessment	O
for	O
an	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
)	O
among	O
high	B:C0018801
-	I:C0018801
risk	I:C0018801
HF	I:C0018801
patients	O
.	O

However	O
,	O
there	O
are	O
limited	O
data	O
on	O
the	O
WCD	O
benefit	O
in	O
the	O
acute	B:C1609524
decompensated	I:C1609524
HF	I:C1609524
setting	O
.	O

The	O
Study	B:C2603343
of	O
the	O
Wearable	O
Cardioverter	O
Defibrillator	O
in	O
Advanced	O
Heart	I:C0018801
-	I:C0018801
Failure	I:C0018801
Patients	O
(	O
SWIFT	O
)	O
was	O
a	O
prospective	O
clinical	O
trial	I:C0008976
carried	O
out	O
at	O
two	O
medical	O
centers	I:C0565990
.	O

The	O
Study	O
of	O
the	O
Wearable	O
Cardioverter	O
Defibrillator	O
in	O
Advanced	B:C0018801
Heart	I:C0018801
-	I:C0018801
Failure	I:C0018801
Patients	O
(	O
SWIFT	O
)	O
was	O
a	O
prospective	O
clinical	O
trial	I:C0008976
carried	O
out	O
at	O
two	O
medical	O
centers	I:C0565990
.	O

The	O
Study	O
of	O
the	O
Wearable	O
Cardioverter	O
Defibrillator	O
in	O
Advanced	O
Heart	I:C0018801
-	I:C0018801
Failure	I:C0018801
Patients	O
(	O
SWIFT	O
)	O
was	O
a	O
prospective	O
clinical	B:C0008976
trial	I:C0008976
carried	O
out	O
at	O
two	O
medical	O
centers	I:C0565990
.	O

The	O
Study	O
of	O
the	O
Wearable	O
Cardioverter	O
Defibrillator	O
in	O
Advanced	O
Heart	I:C0018801
-	I:C0018801
Failure	I:C0018801
Patients	O
(	O
SWIFT	O
)	O
was	O
a	O
prospective	O
clinical	O
trial	I:C0008976
carried	O
out	O
at	O
two	O
medical	B:C0565990
centers	I:C0565990
.	O

Patients	O
hospitalized	O
with	O
advanced	O
HF	B:C0018801
symptoms	O
and	O
reduced	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
(	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
)	O
were	O
enrolled	O
and	O
prescribed	O
a	O
WCD	O
prior	O
to	O
discharge	O
for	O
a	O
total	O
of	O
3	O
months	O
.	O

Patients	O
hospitalized	O
with	O
advanced	O
HF	O
symptoms	B:C1457887
and	O
reduced	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
(	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
)	O
were	O
enrolled	O
and	O
prescribed	O
a	O
WCD	O
prior	O
to	O
discharge	O
for	O
a	O
total	O
of	O
3	O
months	O
.	O

Patients	O
hospitalized	O
with	O
advanced	O
HF	O
symptoms	O
and	O
reduced	O
left	B:C0428772
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
(	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
)	O
were	O
enrolled	O
and	O
prescribed	O
a	O
WCD	O
prior	O
to	O
discharge	O
for	O
a	O
total	O
of	O
3	O
months	O
.	O

Patients	O
hospitalized	O
with	O
advanced	O
HF	O
symptoms	O
and	O
reduced	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
(	O
left	B:C0428772
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
)	O
were	O
enrolled	O
and	O
prescribed	O
a	O
WCD	O
prior	O
to	O
discharge	O
for	O
a	O
total	O
of	O
3	O
months	O
.	O

Patients	O
hospitalized	O
with	O
advanced	O
HF	O
symptoms	O
and	O
reduced	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
(	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
)	O
were	O
enrolled	O
and	O
prescribed	O
a	O
WCD	O
prior	O
to	O
discharge	B:C0030685
for	O
a	O
total	O
of	O
3	O
months	O
.	O

Outcome	O
measures	O
included	O
arrhythmic	O
events	O
,	O
WCD	O
discharge	O
,	O
and	O
death	B:C0011065
.	O

Study	B:C2603343
patients	O
(	O
n=75	O
,	O
mean	O
age	O
51±14	O
years	O
,	O
31	O
%	O
women	O
)	O
had	O
a	O
mean	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
of	O
21.5±10.4	O
%	O
.	O

Study	O
patients	O
(	O
n=75	O
,	O
mean	O
age	O
51±14	O
years	O
,	O
31	O
%	O
women	B:C0043210
)	O
had	O
a	O
mean	O
left	O
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
of	O
21.5±10.4	O
%	O
.	O

Study	O
patients	O
(	O
n=75	O
,	O
mean	O
age	O
51±14	O
years	O
,	O
31	O
%	O
women	O
)	O
had	O
a	O
mean	O
left	B:C0428772
ventricular	I:C0428772
ejection	I:C0428772
function	I:C0428772
of	O
21.5±10.4	O
%	O
.	O

Non-ischemic	B:C0877438
cardiomyopathy	I:C0877438
was	O
present	O
in	O
66	O
%	O
of	O
patients	O
.	O

The	O
median	O
WCD	O
wearing	O
time	O
was	O
59	O
(	O
interquartile	O
range	O
17	O
-	O
97	O
)	O
days	O
,	O
and	O
80	O
%	O
of	O
patients	O
wore	O
the	O
device	B:C0025080
>	O
50	O
%	O
of	O
daily	O
hours	O
.	O

WCD	O
interrogations	O
showed	O
a	O
total	O
of	O
8	O
arrhythmic	O
events	O
in	O
5	O
patients	O
,	O
including	O
3	O
non-sustained	O
or	O
self	B:C1963247
-	I:C1963247
terminating	I:C1963247
ventricular	I:C1963247
tachycardia	I:C1963247
(	I:C1963247
VT	I:C1963247
)	I:C1963247
events	I:C1963247
,	O
and	O
one	O
polymorphic	O
VT	I:C0344432
successfully	O
terminated	O
by	O
the	O
WCD	O
.	O

WCD	O
interrogations	O
showed	O
a	O
total	O
of	O
8	O
arrhythmic	O
events	O
in	O
5	O
patients	O
,	O
including	O
3	O
non-sustained	O
or	O
self	O
-	I:C1963247
terminating	I:C1963247
ventricular	I:C1963247
tachycardia	I:C1963247
(	I:C1963247
VT	I:C1963247
)	I:C1963247
events	I:C1963247
,	O
and	O
one	O
polymorphic	B:C0344432
VT	I:C0344432
successfully	O
terminated	O
by	O
the	O
WCD	O
.	O

None	O
of	O
the	O
patients	O
died	B:C1306577
while	O
wearing	O
the	O
device	O
and	O
no	O
inappropriate	O
device	O
therapies	O
occurred	O
.	O

None	O
of	O
the	O
patients	O
died	O
while	O
wearing	O
the	O
device	B:C0025080
and	O
no	O
inappropriate	O
device	O
therapies	O
occurred	O
.	O

None	O
of	O
the	O
patients	O
died	O
while	O
wearing	O
the	O
device	O
and	O
no	O
inappropriate	O
device	B:C0025080
therapies	O
occurred	O
.	O

None	O
of	O
the	O
patients	O
died	O
while	O
wearing	O
the	O
device	O
and	O
no	O
inappropriate	O
device	O
therapies	B:C0087111
occurred	O
.	O

Upon	O
termination	O
of	O
treatment	O
with	O
the	O
WCD	O
,	O
21	O
patients	O
(	O
28	O
%	O
)	O
received	O
an	O
implantable	B:C0162589
cardioverter	I:C0162589
defibrillator	I:C0162589
.	O

At	O
3	O
years	O
the	O
cumulative	O
death	O
rate	O
was	O
20	O
%	O
in	O
the	O
ischemic	B:C0349782
and	O
21	O
%	O
in	O
non-ischemic	O
cardiomyopathy	I:C0877438
patients	O
.	O

At	O
3	O
years	O
the	O
cumulative	O
death	O
rate	O
was	O
20	O
%	O
in	O
the	O
ischemic	O
and	O
21	O
%	O
in	O
non-ischemic	B:C0877438
cardiomyopathy	I:C0877438
patients	O
.	O

A	O
management	O
strategy	O
incorporating	O
the	O
WCD	O
can	O
be	O
safely	O
used	O
to	O
bridge	O
the	O
decision	O
regarding	O
the	O
need	O
for	O
implantable	B:C0162589
cardioverter	I:C0162589
defibrillator	I:C0162589
implantation	O
in	O
high	O
-	O
risk	O
patients	O
with	O
advanced	O
HF	I:C0018801
.	O

A	O
management	O
strategy	O
incorporating	O
the	O
WCD	O
can	O
be	O
safely	O
used	O
to	O
bridge	O
the	O
decision	O
regarding	O
the	O
need	O
for	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
implantation	B:C0021107
in	O
high	O
-	O
risk	O
patients	O
with	O
advanced	O
HF	I:C0018801
.	O

A	O
management	O
strategy	O
incorporating	O
the	O
WCD	O
can	O
be	O
safely	O
used	O
to	O
bridge	O
the	O
decision	O
regarding	O
the	O
need	O
for	O
implantable	O
cardioverter	I:C0162589
defibrillator	I:C0162589
implantation	O
in	O
high	O
-	O
risk	O
patients	O
with	O
advanced	B:C0018801
HF	I:C0018801
.	O

